Analysis of Nitrosamines in APIsWebinarRegister now!Since 2018, NDMA and other nitrosamines have been observed in a range of different pharmaceuticals. This webinar will look at the chronological development of the story and how nitrosamines have caused the pharmaceutical industry to re-evaluate their manufacturing procedures. It will look at the synthetic pathways that can cause the generation of this range of genotoxins and the regulatory landscape that has evolved as a consequence of the initial findings. We will then discuss the development of a series of applications that will allow for the determination of a range of nitrosamines that have been identified by the FDA as genotoxins to monitor. Key Points Covered:
The webinar will finish with a short Q&A session. For more information, please contact us at amea.webinars@avantorsciences.com Presented By: Tony Edge is the R&D Manager at Avantor, heading a team of specialist scientists in developing next generation stationary phases for HPLC. He has worked in both manufacturing and also industry, having periods of employment at LGC and also AstraZeneca as well as ThermoFisherScientific and latterly Agilent Technologies. In 2008, he was fortunate enough to be awarded the Desty memorial lecture for his contributions to innovating separation science, and in the same year also won a clinical excellence award from AstraZeneca. |
|
Processing your request... |
